title: Auxiliary partial liver transplantation for end-stage chronic liver disease.
abstract: Auxiliary heterotopic liver transplantation is theoretically attractive because it leaves the recipient's liver in place. The surgical trauma of hepatectomy is avoided, and failure of the graft does not necessarily lead to the death of the patient or a second, emergency transplantation. Another advantage is that matching the body sizes of the donor and the recipient is not mandatory, which increases the number of possible donors. However, previous clinical results of auxiliary liver transplantation have been poor. We performed auxiliary partial liver transplantation in six consecutive patients with end-stage chronic liver disease who were not accepted for orthotopic liver transplantation because they had massive ascites, deficient clotting function, cachexia, or poor pulmonary reserve. The donor liver was transplanted to the right subhepatic region after removal of segments II and III, and it was provided with portal and arterial blood. There were no major changes in hemodynamic measurements during surgery. The mean hospital stay after transplantation was 22.7 days (range, 14 to 29). After a mean follow-up period of 14 months (range, 5 to 23), all patients were alive, with good graft function as demonstrated by scintigraphy, Doppler ultrasonography, and synthesis of clotting factors. From these observations we conclude that auxiliary partial liver transplantation is an attractive alternative to orthotopic liver transplantation in high-risk patients. Its role in other patients who need liver transplants remains to be defined.
authors.affiliation: Department of Surgery, University Hospital Dijkzigt, Erasmus University, Rotterdam, the Netherlands.
authors.forename: O T
authors.initials: OT
authors.lastname: Terpstra
authors.forename: S W
authors.initials: SW
authors.lastname: Schalm
authors.forename: W
authors.initials: W
authors.lastname: Weimar
authors.forename: P J
authors.initials: PJ
authors.lastname: Willemse
authors.forename: D
authors.initials: D
authors.lastname: Baumgartner
authors.forename: T H
authors.initials: TH
authors.lastname: Groenland
authors.forename: F W
authors.initials: FW
authors.lastname: ten Kate
authors.forename: R J
authors.initials: RJ
authors.lastname: Porte
authors.forename: S
authors.initials: S
authors.lastname: de Rave
authors.forename: C B
authors.initials: CB
authors.lastname: Reuvers
mesh_terms: D000328:Adult; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000150:complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008103:Liver Cirrhosis / Q000601:surgery; D008107:Liver Diseases / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D008722:Methods; D008875:Middle Aged; D011182:Postoperative Care; D011184:Postoperative Period; D011300:Preoperative Care
chemical_list: D007166:Immunosuppressive Agents